Mersana Therapeutics Inc. (NASDAQ:MRSN) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) compete against each other in the Biotechnology sector. We will compare them and contrast their dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation.
Valuation and Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Mersana Therapeutics Inc.||4||2.63||N/A||-1.55||0.00|
|BioMarin Pharmaceutical Inc.||84||8.64||N/A||-0.50||0.00|
We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Mersana Therapeutics Inc. and BioMarin Pharmaceutical Inc.
Table 2 provides the net margins, return on assets and return on equity of the two firms.
|Net Margins||Return on Equity||Return on Assets|
|Mersana Therapeutics Inc.||0.00%||-57.5%||-27.9%|
|BioMarin Pharmaceutical Inc.||0.00%||-3.1%||-2%|
Mersana Therapeutics Inc. has a Current Ratio of 6.2 and a Quick Ratio of 6.2. Competitively, BioMarin Pharmaceutical Inc.’s Current Ratio is 3.8 and has 2.8 Quick Ratio. Mersana Therapeutics Inc.’s better ability to pay short and long-term obligations than BioMarin Pharmaceutical Inc.
Mersana Therapeutics Inc. and BioMarin Pharmaceutical Inc. Ratings and Recommendations are available on the next table.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Mersana Therapeutics Inc.||0||0||0||0.00|
|BioMarin Pharmaceutical Inc.||0||0||3||3.00|
Meanwhile, BioMarin Pharmaceutical Inc.’s average price target is $129.33, while its potential upside is 78.63%.
Insider & Institutional Ownership
Institutional investors held 79.4% of Mersana Therapeutics Inc. shares and 0% of BioMarin Pharmaceutical Inc. shares. Competitively, BioMarin Pharmaceutical Inc. has 0.6% of it’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Mersana Therapeutics Inc.||-8.62%||-16.47%||-30.83%||-23.58%||-68.89%||-14.22%|
|BioMarin Pharmaceutical Inc.||-2.19%||-5.74%||-5.77%||-18.2%||-20.19%||-6.85%|
For the past year Mersana Therapeutics Inc.’s stock price has bigger decline than BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. beats Mersana Therapeutics Inc. on 7 of the 8 factors.
Mersana Therapeutics, Inc. is a biotechnology company that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company develops immune conjugate therapies to create drugs that enhance patientsÂ’ lives. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck Serono; and Asana BioSciences. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Aldurazyme used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), an inherited metabolic disease; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; and Vimizim, an enzyme replacement therapy for the treatment of MPS IV A, a lysosomal storage disorder. The company also conducts clinical trials on several investigational product candidates for the treatment of various diseases, including Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis, a form of Batten disease; pegvaliase, an enzyme substitution therapy for the treatment of PKU; vosoritide, a peptide therapeutic for the treatment of achondroplasia; BMN 270, an AAV VIII vector and Factor VIII gene therapy drug development candidate, for the treatment of hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase for the treatment of Sanfilippo B syndrome, or mucopolysaccharidosis type IIIB. The company serves specialty pharmacies and end-users, such as hospitals and foreign government agencies; and distributors and pharmaceutical wholesalers. BioMarin Pharmaceutical Inc. has a collaboration agreement with Genzyme Corporation. The company was founded in 1996 and is headquartered in San Rafael, California.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.